Ma Jin-Bao, Zeng Ling-Cheng, Ren Fei, Dang Li-Yun, Luo Hui, Wu Yan-Qin, Yang Xin-Jun, Li Rong, Yang Han, Xu You
Department of Drug-Resistance Tuberculosis, Xi'an Chest Hospital, Xi'an, People's Republic of China.
Xi'an Center for Disease Control and Prevention, Xi'an, People's Republic of China.
Infect Drug Resist. 2022 Aug 29;15:4947-4957. doi: 10.2147/IDR.S376177. eCollection 2022.
Long-term regimens are widely used for multidrug-resistant tuberculosis (MDR-TB) in North-West China; however, risk factors associated with the treatment outcomes are not well known.
This was a retrospective cohort study of MDR-TB patients treated with longer regimen in Xi'an from 2017 to 2019. Risk factors associated with the treatment outcome were analyzed using multiple logistic regression.
Of the 446 patients with MDR-TB included, 215 were cured, 84 completed treatment, 23 failed treatment, 108 were lost to follow-up, and 16 died. Unfavorable outcome risk factors were age >40 years (OR = 3.25, 95% CI = 2.12-4.98), male sex (OR = 2.53, 95% CI = 1.52-4.22), and re-treated tuberculosis (OR = 1.70, 95% CI = 1.11-2.61), whereas poor treatment outcome risk factors were age >40 years (OR = 5.51, 95% CI = 2.52-12.07), fluoroquinolones not used in the regimen (OR = 3.31, 95% CI = 1.45-7.51), and smear-positive (OR = 4.0, 95% CI = 1.47-10.8).
In Xi'an, MDR-TB treatments with long-term regimens had low success rates, and age, sex, and tuberculosis treatment history were risk factors of MDR-TB treatment outcomes.
在中国西北部,长期治疗方案被广泛用于耐多药结核病(MDR-TB)的治疗;然而,与治疗结果相关的风险因素尚不明确。
这是一项对2017年至2019年在西安接受较长疗程治疗的耐多药结核病患者的回顾性队列研究。使用多因素逻辑回归分析与治疗结果相关的风险因素。
纳入的446例耐多药结核病患者中,215例治愈,84例完成治疗,23例治疗失败,108例失访,16例死亡。不良结局的风险因素为年龄>40岁(OR = 3.25,95%CI = 2.12 - 4.98)、男性(OR = 2.53,95%CI = 1.52 - 4.22)和复治结核病(OR = 1.70,95%CI = 1.11 - 2.61),而治疗效果不佳的风险因素为年龄>40岁(OR = 5.51,95%CI = 2.52 - 12.07)、治疗方案中未使用氟喹诺酮类药物(OR = 3.31,95%CI = 1.45 - 7.51)和涂片阳性(OR = 4.0,95%CI = 1.47 - 10.8)。
在西安,长期治疗方案的耐多药结核病治疗成功率较低,年龄、性别和结核病治疗史是耐多药结核病治疗结果的风险因素。